Incorporating commercial and private data into an open linked data platform for drug discovery

Carole Goble, Alasdair J G Gray, Lee Harland, Karen Karapetyan, Antonis Loizou, Ivan Mikhailov, Yrjänä Rankka, Stefan Senger, Valery Tkachenko, Antony J. Williams, Egon L. Willighagen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The Open PHACTS Discovery Platform aims to provide an integrated information space to advance pharmacological research in the area of drug discovery. Effective drug discovery requires comprehensive data coverage, i.e. integrating all available sources of pharmacology data. While many relevant data sources are available on the linked open data cloud, their content needs to be combined with that of commercial datasets and the licensing of these commercial datasets respected when providing access to the data. Additionally, pharmaceutical companies have built up their own extensive private data collections that they require to be included in their pharmacological dataspace. In this paper we discuss the challenges of incorporating private and commercial data into a linked dataspace: focusing on the modelling of these datasets and their interlinking. We also present the graph-based access control mechanism that ensures commercial and private datasets are only available to authorized users.
LanguageEnglish
Title of host publicationIncorporating commercial and private data into an open linked data platform for drug discovery
PublisherSpringer
Pages65-80
Number of pages16
Volume8219
ISBN (Print)9783642413377
DOIs
Publication statusPublished - 2013

Publication series

NameLecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)
Volume8219 LNCS

Fingerprint

Access control
Drug products
Industry
Drug Discovery

Cite this

Goble, C., Gray, A. J. G., Harland, L., Karapetyan, K., Loizou, A., Mikhailov, I., ... Willighagen, E. L. (2013). Incorporating commercial and private data into an open linked data platform for drug discovery. In Incorporating commercial and private data into an open linked data platform for drug discovery (Vol. 8219, pp. 65-80). (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics); Vol. 8219 LNCS). Springer. https://doi.org/10.1007/978-3-642-41338-4_5
Goble, Carole ; Gray, Alasdair J G ; Harland, Lee ; Karapetyan, Karen ; Loizou, Antonis ; Mikhailov, Ivan ; Rankka, Yrjänä ; Senger, Stefan ; Tkachenko, Valery ; Williams, Antony J. ; Willighagen, Egon L. / Incorporating commercial and private data into an open linked data platform for drug discovery. Incorporating commercial and private data into an open linked data platform for drug discovery. Vol. 8219 Springer, 2013. pp. 65-80 (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)).
@inbook{1fb917788d554cd1937da1cd3c719f22,
title = "Incorporating commercial and private data into an open linked data platform for drug discovery",
abstract = "The Open PHACTS Discovery Platform aims to provide an integrated information space to advance pharmacological research in the area of drug discovery. Effective drug discovery requires comprehensive data coverage, i.e. integrating all available sources of pharmacology data. While many relevant data sources are available on the linked open data cloud, their content needs to be combined with that of commercial datasets and the licensing of these commercial datasets respected when providing access to the data. Additionally, pharmaceutical companies have built up their own extensive private data collections that they require to be included in their pharmacological dataspace. In this paper we discuss the challenges of incorporating private and commercial data into a linked dataspace: focusing on the modelling of these datasets and their interlinking. We also present the graph-based access control mechanism that ensures commercial and private datasets are only available to authorized users.",
author = "Carole Goble and Gray, {Alasdair J G} and Lee Harland and Karen Karapetyan and Antonis Loizou and Ivan Mikhailov and Yrj{\"a}n{\"a} Rankka and Stefan Senger and Valery Tkachenko and Williams, {Antony J.} and Willighagen, {Egon L.}",
year = "2013",
doi = "10.1007/978-3-642-41338-4_5",
language = "English",
isbn = "9783642413377",
volume = "8219",
series = "Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)",
publisher = "Springer",
pages = "65--80",
booktitle = "Incorporating commercial and private data into an open linked data platform for drug discovery",

}

Goble, C, Gray, AJG, Harland, L, Karapetyan, K, Loizou, A, Mikhailov, I, Rankka, Y, Senger, S, Tkachenko, V, Williams, AJ & Willighagen, EL 2013, Incorporating commercial and private data into an open linked data platform for drug discovery. in Incorporating commercial and private data into an open linked data platform for drug discovery. vol. 8219, Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 8219 LNCS, Springer, pp. 65-80. https://doi.org/10.1007/978-3-642-41338-4_5

Incorporating commercial and private data into an open linked data platform for drug discovery. / Goble, Carole; Gray, Alasdair J G; Harland, Lee; Karapetyan, Karen; Loizou, Antonis; Mikhailov, Ivan; Rankka, Yrjänä; Senger, Stefan; Tkachenko, Valery; Williams, Antony J.; Willighagen, Egon L.

Incorporating commercial and private data into an open linked data platform for drug discovery. Vol. 8219 Springer, 2013. p. 65-80 (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics); Vol. 8219 LNCS).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Incorporating commercial and private data into an open linked data platform for drug discovery

AU - Goble, Carole

AU - Gray, Alasdair J G

AU - Harland, Lee

AU - Karapetyan, Karen

AU - Loizou, Antonis

AU - Mikhailov, Ivan

AU - Rankka, Yrjänä

AU - Senger, Stefan

AU - Tkachenko, Valery

AU - Williams, Antony J.

AU - Willighagen, Egon L.

PY - 2013

Y1 - 2013

N2 - The Open PHACTS Discovery Platform aims to provide an integrated information space to advance pharmacological research in the area of drug discovery. Effective drug discovery requires comprehensive data coverage, i.e. integrating all available sources of pharmacology data. While many relevant data sources are available on the linked open data cloud, their content needs to be combined with that of commercial datasets and the licensing of these commercial datasets respected when providing access to the data. Additionally, pharmaceutical companies have built up their own extensive private data collections that they require to be included in their pharmacological dataspace. In this paper we discuss the challenges of incorporating private and commercial data into a linked dataspace: focusing on the modelling of these datasets and their interlinking. We also present the graph-based access control mechanism that ensures commercial and private datasets are only available to authorized users.

AB - The Open PHACTS Discovery Platform aims to provide an integrated information space to advance pharmacological research in the area of drug discovery. Effective drug discovery requires comprehensive data coverage, i.e. integrating all available sources of pharmacology data. While many relevant data sources are available on the linked open data cloud, their content needs to be combined with that of commercial datasets and the licensing of these commercial datasets respected when providing access to the data. Additionally, pharmaceutical companies have built up their own extensive private data collections that they require to be included in their pharmacological dataspace. In this paper we discuss the challenges of incorporating private and commercial data into a linked dataspace: focusing on the modelling of these datasets and their interlinking. We also present the graph-based access control mechanism that ensures commercial and private datasets are only available to authorized users.

U2 - 10.1007/978-3-642-41338-4_5

DO - 10.1007/978-3-642-41338-4_5

M3 - Chapter

SN - 9783642413377

VL - 8219

T3 - Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)

SP - 65

EP - 80

BT - Incorporating commercial and private data into an open linked data platform for drug discovery

PB - Springer

ER -

Goble C, Gray AJG, Harland L, Karapetyan K, Loizou A, Mikhailov I et al. Incorporating commercial and private data into an open linked data platform for drug discovery. In Incorporating commercial and private data into an open linked data platform for drug discovery. Vol. 8219. Springer. 2013. p. 65-80. (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)). https://doi.org/10.1007/978-3-642-41338-4_5